A human tamoxifen-resistant breast cancer model used to study endocrine resistance, oestrogen receptor signalling, and hormone-directed therapies. Save 30% on this cell line this autumn. Use code ACA26CELL at checkout.
| Inventor | Institute |
|---|---|
| Anne Lykkesfeldt | Danish Cancer Society, Denmark |
| SKU: | 152088 |
|---|---|
| Product description: | MCF7/TAMR-4 cell line is a stable tamoxifen-resistant subline. This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxifen resistant cancer growth. MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative, and are growth inhibited by the pure antioestrogen fulvestrant. MCF7/TAMR-4 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance. Additionally, this line can aid in identifying new predictive markers for response to hormonal therapy. |
| Alternate name: | MCF-7/TAMR-4 Cell Line |
| Gender: | Female |
| Conditional: | Yes |
| Production details: | The parental cell line for the MCF7/TAMR-4 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-4 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line. |
| Additional notes: | MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment wi… |
| Cellosaurus ID: | CVCL_1D42 |
| Parental cell line: | MCF7 S0.5 |
| Disease: | Cancer |
| Cat. #: | 152088 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Organism: | Human |
| Tissue: | Breast |
| Gender: | Female |
| Model: | Tumour line |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM:Ham’s F-12 phenol red-free medium containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM). |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| Recommended controls: | MCF7-S0.5 parental line |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Joshi et al. 2016. Oncotarget. 7(35):57239-57253. PMID: 27528030. Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577. Thrane et al. 2015. Oncogene. 34:4199–4210. PMID: 25362855. Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470. Cutrupi et al. 2012. Oncogene. 31(40):4353-4361. PMID: 22249258. Millour et al. 2010. Oncogene. 29(20):2983-2995. PMID: 20208560. Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559. Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-861. PMID: 16954434. |
|---|
| Cat. # | Tool Name | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152086 | MCF7/TAMR-8 Cell Line |
Key Info
MCF7/TAMR-8 Cell Line
|
View Tool | |||||||||||
| 152087 | MCF7/TAMR-7 Cell line |
Key Info
MCF7/TAMR-7 Cell line
|
View Tool | |||||||||||
| 152089 | MCF7/TAMR-1 Cell Line |
Key Info
MCF7/TAMR-1 Cell Line
|
View Tool | |||||||||||
| 152090 | MCF7/S0.5 Cell Line |
Key Info
MCF7/S0.5 Cell Line
|
View Tool | |||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.